Previous close | 0.9400 |
Open | 0.8000 |
Bid | 0.0000 |
Ask | 2.1500 |
Strike | 3.50 |
Expiry date | 2026-01-16 |
Day's range | 0.8000 - 0.9400 |
Contract range | N/A |
Volume | |
Open interest | 70 |
Key Insights Institutions' substantial holdings in Geron implies that they have significant influence over the...
Geron's (GERN) shares rise on approval of its first drug. The FDA approves imetelstat for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.
Shares of Geron (GERN) are trading higher Friday, propelled by the recent Food & Drug Administration (FDA) approval of the company's blood disorder drug, Rytelo. The treatment is for adults with low- to intermediate-1 risk of myelodysplastic syndromes, a type of cancer. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Angel Smith